Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced that it has launched ZYFLO CR(TM) (zileuton) extended release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older.
Dey L.P. And Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets For The Chronic Treatment Of Asthma
0 comments :
Post a Comment